ArticleOncoTargets and therapy2026
A Nomogram Integrating HOXA9 Expression and Clinicopathological Factors for Predicting Postoperative Recurrence in Gastric Cancer: A Single-Center Retrospective Study.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop a nomogram integrating HOXA9 expression with clinicopathological indicators for predicting postoperative recurrence risk in gastric cancer. Methods: This single-center retrospective study enrolled 152 gastric cancer patients who underwent radical surgery (June 2023-March 2024) with 18-month follow-up. Patients were divided into recurrence (n=58) and non-recurrence (n=94) groups. HOXA9 expression was assessed by immunohistochemistry. Clinicopathological parameters including age, gender, tumor size, location, differentiation, invasion depth, lymph node metastasis, TNM stage, vascular invasion, and perineural invasion were collected. Univariate and multivariate Cox regression and ROC analyses were used to identify independent risk factors and evaluate predictive value. Results: The recurrence rate was 38.16%. The recurrence group had significantly larger tumor size, higher proportions of poor differentiation, lymph node metastasis, TNM stage III, vascular invasion, perineural invasion, and high HOXA9 expression (all P<0.05). Multivariate Cox regression identified lymph node metastasis [HR=1.206 (1.042-1.397)], TNM stage III [HR=1.598 (1.096-2.328)], vascular invasion [HR=1.863 (1.093-3.176)], and high HOXA9 expression [HR=2.076 (1.222-3.525)] as independent risk factors (P<0.05). The combined AUC was 0.798, significantly higher than each factor alone (Z=3.472-3.305, all P<0.01). Conclusion: The model combining HOXA9 expression with TNM stage, lymph node metastasis, and vascular invasion demonstrates good performance in assessing postoperative recurrence risk and may serve as a practical tool for clinical risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.